Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
22,214,575
-
Share change
-
+548,295
-
Total reported value
-
$123,732,000
-
Price per share
-
$5.57
-
Number of holders
-
65
-
Value change
-
+$988,222
-
Number of buys
-
30
-
Number of sells
-
35
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q4 2018
As of 31 Dec 2018,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,214,575 shares.
The largest 10 holders included
FMR LLC, Flagship Pioneering Inc., ARK Investment Management LLC, BlackRock Inc., Redmile Group, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Samsara BioCapital, LLC, Vanguard Group Inc, BAKER BROS. ADVISORS LP, and STATE STREET CORP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.